The use of recombinant activated factor VII in the control of haemorrhage following blunt pelvic trauma.
This article reports two cases of severe blunt pelvic trauma associated with road traffic accidents, where the patients developed significant bleeding and haemodynamic instability, poorly responsive to conventional management. Both patients required massive transfusion of blood products with a resultant dilutional coagulopathy. In each case, a single dose of recombinant activated factor VII (rFVIIa) was used to achieve haemostatic control, with a subsequent decrease in blood product requirements and improvement in haemoglobin concentration and clotting profile.
Udy
A
A
Department of Anaesthesia, Kent and Sussex Hospital, Tunbridge Wells, UK. andrew@udy.com
Vaghela
M
M
Lawton
G
G
Sigston
P
P
D000063:Accidents, Traffic; D000293:Adolescent; D000328:Adult; D005167:Factor VII / Q000627:therapeutic use*; D015942:Factor VIIa; D006470:Hemorrhage / Q000188:drug therapy* / Q000209:etiology; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D010384:Pelvic Bones / Q000293:injuries*; D010388:Pelvis / Q000293:injuries; D017713:Platelet Transfusion; D011994:Recombinant Proteins / Q000627:therapeutic use*; D014949:Wounds, Nonpenetrating / Q000150:complications* / Q000601:surgery
D006490:Hemostatics; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa